Journals / Türk Nöroloji Dergisi / 2018 / Cilt: 24 - Sayı: 2

Chronic Migraine: Burden, Comorbidities, and Treatment

Kronik Migren: Hastalık Yükü, Komorbidite ve Tedavi

Pages
117–125
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the disease burden of CM, accompanying comorbid diseases, and current treatment options are reviewed

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic migraine (CM) is defined as headache occurring on 15 or more days per month for more than three months, which, on at least 8 days per month, has the features of migraine headache.
📊
Key Findings & Data:In the International Classification of Headache Disorders, CM is defined as a separate entity and the presence of drug overuse headache is removed from being an exclusion criterion.
💡
Conclusion & Impact:In this review, the disease burden of CM, accompanying comorbid diseases, and current treatment options are reviewed
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Chronic migraine (CM) is defined as headache occurring on 15 or more days per month for more than three months, which, on at least 8 days per month, has the features of migraine headache. In the International Classification of Headache Disorders, CM is defined as a separate entity and the presence of drug overuse headache is removed from being an exclusion criterion. CM accounts for more than 10% of all migraine patients and includes the group with the most prominent disease-related disability. Diagnosis is often overlooked and most patients do not receive appropriate treatment. CM is associated with social and economic burdens such as frequent use of health services, drug overuse, and significant disruption to work and school life. Compared with episodic migraine, more frequent comorbid disorders are important in migraine chronicity, treatment, and course. With appropriate treatment in CM, it is possible to increase the quality of life of the patient and to reduce the social economic burden associated with migraine. In this review, the disease burden of CM, accompanying comorbid diseases, and current treatment options are reviewed

Özet

Kronik migren (KM) ayda 15 gün ve daha sık görülen baş ağrılarının 3 aydan uzun süredir devam etmesi ve 8 veya daha fazla gün baş ağrısının migren özellikleri taşıması ile tanımlanmaktadır. Uluslararası Baş Ağrısı Sınıflandırması’nda KM ayrı bir antite olarak tanımlanmış ve ilaç aşırı kullanımı baş ağrısı varlığı bir dışlama kriteri olmaktan çıkarılmıştır. KM tüm migren hastalarının %10’dan fazlasını oluşturmaktadır ve hastalık ilişkili özürlülüğün en belirgin olduğu grubu içermektedir. Tanı sıklıkla atlanmakta ve çoğu hasta uygun tedavi almamaktadır. KM sağlık hizmetlerinin sık kullanımı, ilaç aşırı kullanımı, iş ve okul hayatında belirgin aksama gibi sosyal ve ekonomik yük ile ilişkilidir. Epizodik migren ile karşılaştırıldığında daha sık gözlenen komorbid bozukluklar migren kronikleşmesinde, tedavisinde ve seyrinde önemlidir. KM’de uygun tedavi ile hastanın yaşam kalitesinde artış ve migren ilişkili toplumsal ekonomik yükün azaltılması sağlanabilir. Bu derlemede KM’nin hastalık yükü, eşlik eden komorbid hastalıklar ve güncel tedavi seçenekleri gözden geçirilmiştir.

🔖

Cite This Article

SİVA, A., KARADAŞ, Ö., DEMİRCİ, S., ULUDÜZ, D., UYGUNOĞLU, U., ÖZGE, A., YALIN, O. Ö. (2022). Chronic Migraine: Burden, Comorbidities, and Treatment. Türk Nöroloji Dergisi, Cilt: 24 - Sayı: 2, 117–125. https://ajindex.com/articles/636797

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-936.
  2. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-814.
  3. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
  4. Ashkenazi A, Blumenfeld A. OnabotulinumtoxinA for the treatment of headache. Headache 2013;53:54-61. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-793.
  5. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006;122:315-325
  6. Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults. Cochrane Database Syst Rev 2015;4:CD011681. Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Database Syst Rev 2015;4:CD002919. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 2008;9:37-41.
  7. Edvardsson, B. Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study. Springerplus 2013;2:479. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23:820-824.
  8. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27:814-823.
  9. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Jordan DM. Topiramate Chro